October 23, 2012 – Brussels – AJC welcomes the European Parliament’s approval of ACAA, a technical agreement between the European Union (EU) and Israel designed to facilitate pharmaceutical trade. The measure passed by a margin of 379-230.
“Israeli pharmaceutical companies are at the cutting edge of research, developing innovative treatments that help save lives and reduce suffering,” said Daniel Schwammenthal, Director of AJC’s Transatlantic Institute in Brussels.
”Through their leadership in the generics market, Israeli medicines help healthcare providers reduce spending while maintaining high quality standards.” Schwammenthal said. "This is a good day for both Israel and the EU."
The European Council, comprised of the heads of the 27 EU Member States, agreed to the ACAA protocol in March 2010 and referred it to the European Parliament for action. The file sat in the Parliament’s Committee on International Trade for over two years until a vote was held on September 18, 2012, in which a majority of deputies gave their consent.
“At its core, this was not a debate on the merits of the agreement. This was about politics,” said Schwammenthal. “Some Members of the European Parliament were putting their disagreements with Israel ahead of their obligations to ensure their constituents had fast access to the best and most affordable healthcare. ACAA is simply about the interests of European patients.”